SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
05 07 2021
Historique:
entrez: 6 7 2021
pubmed: 7 7 2021
medline: 10 7 2021
Statut: epublish

Résumé

To assess the SARS-CoV-2 transmission in healthcare workers (HCWs) using seroprevalence as a surrogate marker of infection in our tertiary care centre according to exposure. Seroprevalence cross-sectional study. Single centre at the end of the first COVID-19 wave in Lausanne, Switzerland. 1874 of 4074 responders randomly selected (46% response rate), stratified by work category among the 13 474 (13.9%) HCWs. Evaluation of SARS-CoV-2 serostatus paired with a questionnaire of SARS-CoV-2 acquisition risk factors internal and external to the workplace. The overall SARS-CoV-2 seroprevalence rate among HCWs was 10.0% (95% CI 8.7% to 11.5%). HCWs with daily patient contact did not experience increased rates of seropositivity relative to those without (10.3% vs 9.6%, respectively, p=0.64). HCWs with direct contact with patients with COVID-19 or working in COVID-19 units did not experience increased seropositivity rates relative to their counterparts (10.4% vs 9.8%, p=0.69 and 10.6% vs 9.9%, p=0.69, respectively). However, specific locations of contact with patients irrespective of COVID-19 status-in patient rooms or reception areas-did correlate with increased rates of seropositivity (11.9% vs 7.5%, p=0.019 and 14.3% vs 9.2%, p=0.025, respectively). In contrast, HCWs with a suspected or proven SARS-CoV-2-infected household contact had significantly higher seropositivity rates than those without such contacts (19.0% vs 8.7%, p<0.001 and 42.1% vs 9.4%, p<0.001, respectively). Finally, consistent use of a mask on public transportation correlated with decreased seroprevalence (5.3% for mask users vs 11.2% for intermittent or no mask use, p=0.030). The overall seroprevalence was 10% without significant differences in seroprevalence between HCWs exposed to patients with COVID-19 and HCWs not exposed. This suggests that, once fully in place, protective measures limited SARS-CoV-2 occupational acquisition within the hospital environment. SARS-CoV-2 seroconversion among HCWs was associated primarily with community risk factors, particularly household transmission.

Identifiants

pubmed: 34226231
pii: bmjopen-2021-049232
doi: 10.1136/bmjopen-2021-049232
pmc: PMC8260307
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e049232

Investigateurs

Oliver Peters (O)
Michael Currat (M)
Laurence Posset (L)
Fady Fares (F)
Vassili Soumas (V)
Séverine Bignon (S)
Elisa Corne (E)
Michael Currat (M)
Joana Da Silva Quelhas (JDS)
Allan Dussex (A)
Dominique Ker (D)
Patricia Mosset (P)
Estelle Moulin (E)
Eugénie Prouvost (E)
Kyllian Ruscio (K)
Sandrine Piccon (S)
Fleur Valterio (F)
Emilie Allain (E)
Charles Guay (C)
Zahra Hezari (Z)
Yoann Levet (Y)
Laurence Posset (L)
Marie-Agnès Prevost (MA)
Adeline Rognon (A)
Homa Salehi-Gysel (H)
Cécile Starck (C)
Aurélie Tornier (A)
Sara Torres da Fonseca (ST)
Aline Udriot (A)

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Infect Dis. 2020 Aug 11;:
pubmed: 32780799
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Clin Infect Dis. 2020 Dec 3;71(9):2311-2313
pubmed: 32628269
MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1605-1610
pubmed: 33119557
Pathog Dis. 2020 Nov 11;78(8):
pubmed: 33030200
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Science. 2020 Oct 16;370(6514):303-304
pubmed: 33020250
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
BMJ. 2020 Oct 23;371:m3862
pubmed: 33097561
Clin Infect Dis. 2021 May 4;72(9):1645-1648
pubmed: 32628750
JAMA. 2020 Aug 18;324(7):703-704
pubmed: 32663246
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
BMJ Glob Health. 2020 May;5(5):
pubmed: 32467353
Lancet Glob Health. 2020 Jun;8(6):e790-e798
pubmed: 32573443
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
EClinicalMedicine. 2020 May 11;23:100390
pubmed: 32395708
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Lancet Infect Dis. 2020 Nov;20(11):1273-1280
pubmed: 32622380
Nature. 2020 Apr;580(7802):175
pubmed: 32242113
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Lancet Public Health. 2020 May;5(5):e253
pubmed: 32220653
Lancet Respir Med. 2020 Sep;8(9):885-894
pubmed: 32717210
Anesthesiology. 2020 Jul;133(1):244-246
pubmed: 32235155

Auteurs

Sylvain Meylan (S)

Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland sylvain.meylan@chuv.ch.

Urania Dafni (U)

Laboratory of Biostatistics, School of Health Sciences, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece.

Frederic Lamoth (F)

Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Zoi Tsourti (Z)

Laboratory of Biostatistics, School of Health Sciences, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece.

Michael A Lobritz (MA)

Roche Biomedical, Basel, Switzerland.

Jean Regina (J)

Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Philippe Bressin (P)

Occupational Health Service, Lausanne University Hospital, Lausanne, Switzerland.

Laurence Senn (L)

Service of Hospital Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Bruno Grandbastien (B)

Service of Hospital Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland.

Cyril Andre (C)

Immunology Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Craig Fenwick (C)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Valerie D'Acremont (V)

Department of Ambulatory Care and Community Medicine, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.

Antony Croxatto (A)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Isabelle Guilleret (I)

Clinical Trial Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Gilbert Greub (G)

Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Oriol Manuel (O)

Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Thierry Calandra (T)

Infectious Diseases Service, Internal Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Giuseppe Pantaleo (G)

Immunology Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Catherine Lazor-Blanchet (C)

Occupational Health Service, Lausanne University Hospital, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH